Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Exp Dermatol ; 31(4): 485-497, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35174548

RESUMO

Aryl hydrocarbon receptor (AHR)/nuclear factor-erythroid 2-related factor 2 (NRF2) modulation is emerging as novel targets in the treatment of atopic dermatitis and other inflammatory skin disorders. Agonist activation of this pathway has downstream effects on epidermal barrier function, immunomodulation, oxidative stress reduction and cutaneous microbiome modulation. Tapinarof, a dual agonist of the AHR/NRF2 signalling pathway, has shown promise in phase 2 trials for atopic dermatitis. In this review, we summarize current knowledge of the AHR/NRF2 pathway and implications in skin disease process. We also review the therapeutic potential of current AHR agonists and propose future directions to address knowledge gaps.


Assuntos
Dermatite Atópica , Dermatopatias , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/metabolismo , Humanos , Fator 2 Relacionado a NF-E2/metabolismo , Receptores de Hidrocarboneto Arílico/metabolismo , Transdução de Sinais , Pele/metabolismo , Dermatopatias/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...